SCI时时刷

search
Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma
Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma
Multiple Myeloma (MM) is characterized by a great clinical and genetic heterogeneity [1]. The disease rem...
ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
Deletion of ABL1 was detected in a cohort of hematologic malignancies carrying AML1-ETO and NUP98 fusion proteins. Abl1...
CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study
Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults w...
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory...
Multiple myeloma with t(11;14): impact of novel agents on outcome
Multiple myeloma with t(11;14): impact of novel agents on outcome
Multiple myeloma (MM) patients with t(11;14) present unique biological features and their prognosis is not well establishe...
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm
The basis of the NCCN recommendation is that 2G-TKIs lead to improved molecular and cytogenetic responses in CML patients....
MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas
MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas
The paracaspase mucosa-associated lymphoid tissue 1 (MALT1) is a protease and scaffold protein essential in propagating B-...
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic
The COVID-19 pandemic has had global healthcare impacts, including high mortality from SARS-CoV-2 infection in cancer pati...
Infectious complications of bispecific antibody therapy in patients with multiple myeloma
We identified 39 MM patients who received BsAb therapy at our centre with median follow-up of 152 (IQR 51–277) days. The m...
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
Minimal residual disease (MRD) assays allow response assessment in patients with multiple myeloma (MM), and negativity is ...
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy
Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatmen...
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry
Minimal residual disease (MRD) assessment has been established as a prognostic indicator for multiple mye...
Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance
Monoclonal gammopathy of undetermined significance (MGUS) is a benign hematological condition with the potential to progre...
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
Constant challenges for the treatment of mantle cell lymphoma (MCL) remain to be recurrent relapses and therapy resistance...
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
These authors contributed equally: Keiji Kurata, Anna James-Bott.Jerome Lipper Multiple Myeloma Center, LeBow Institute fo...
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors
PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpr...
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
Somatic mutations in calreticulin (CALR), encoding for the reticulum-endoplasmic-associated Ca2+-binding ...
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Functional perturbations of the cohesin complex with subsequent changes in chromatin structure and replication are reporte...
Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway
Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathway
Alternative splicing plays a pivotal role in tumorigenesis and proliferation. However, its pattern and pathogenic role has...